Chosa Oncology AB (XSAT:CHOSA) EBIT per Share: kr-0.02 (TTM As of Mar. 2026)


XSAT:CHOSA Chosa Oncology AB XSAT:CHOSA
31 GF Score
Price kr0.75
View Full Analysis

What is Chosa Oncology AB EBIT per Share?

Chosa Oncology AB XSAT:CHOSA 31 EBIT per Share is kr-0.02 as of Mar. 2026. GuruFocus rates XSAT:CHOSA with a GF Score™ of 31/100. Among 1,172 Biotechnology companies, Chosa Oncology AB ranks worse than 82.42% on this metric.

Chosa Oncology AB's EBIT per Share for the three months ended in Mar. 2026 was kr-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was -13.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 52.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 23.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Chosa Oncology AB's EBIT per Share or its related term are showing as below:

XSAT:CHOSA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -101.4   Med: -13.2   Max: 71.5
Current: -13.8

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Chosa Oncology AB was 71.50% per year. The lowest was -101.40% per year. And the median was -13.20% per year.

XSAT:CHOSA's 3-Year EBIT Growth Rate is ranked worse than
82.42% of 1172 companies
in the Biotechnology industry
Industry Median: 15.35 vs XSAT:CHOSA: -13.80

Chosa Oncology AB's EBIT for the three months ended in Mar. 2026 was kr-1.87 Mil.

Chosa Oncology AB  (XSAT:CHOSA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Chosa Oncology AB EBIT per Share Related Terms

Chosa Oncology AB EBIT per Share Historical Data

* Premium members only.

The historical data trend for Chosa Oncology AB's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chosa Oncology AB EBIT per Share Chart

Chosa Oncology AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.05 -0.06 -0.35 -0.08 -0.09

Chosa Oncology AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.04 -0.03 0.00 -0.02
XSAT:CHOSA
31GF Score
Chosa Oncology AB XSAT:CHOSA
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chosa Oncology AB EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Chosa Oncology AB's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-6.62/74.471
=-0.09

Chosa Oncology AB's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.866/88.952
=-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of kr-0.02 mean?
Chosa Oncology AB (XSAT:CHOSA) has a EBIT per Share of kr-0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chosa Oncology AB and its competitors. According to the industry distribution chart, Chosa Oncology AB ranks #966 out of 1172 companies in the Biotechnology industry, placing it in the top 82.4%.
Is Chosa Oncology AB's EBIT per Share too high?
Chosa Oncology AB's current EBIT per Share is kr-0.02. Based on the distribution chart, Chosa Oncology AB ranks #966 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chosa Oncology AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Chosa Oncology AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chosa Oncology AB ranks #966 out of 1172 companies for EBIT per Share. This places Chosa Oncology AB in the lower half of its industry. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chosa Oncology AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chosa Oncology AB's current EBIT per Share is kr-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chosa Oncology AB stock overvalued right now?
Chosa Oncology AB (XSAT:CHOSA) has a current EBIT per Share of kr-0.02. The current EBIT per Share is kr-0.02. Chosa Oncology AB's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Chosa Oncology AB (XSAT:CHOSA), the current EBIT per Share is kr-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chosa Oncology AB Business Description

Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Chosa Oncology AB is a biotechnology company engaged in the research and development in immunotherapy on therapeutic cancer vaccines.
31GF Score

Get the complete analysis for XSAT:CHOSA

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.75
Price